This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Stryker (SYK) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Stryker (SYK) delivered earnings and revenue surprises of 1.22% and 0.74%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Baxter (BAX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Higher revenues, solid product portfolio and strong performance across six global business units are likely to have benefited Baxter's (BAX) Q4 earnings.
Robotics to Take Centerstage in 2020: 5 Stocks in Focus
by Sreoshi Bera
The global robotics market is expected to see a CAGR of 25% between 2019 and 2024 on increased human and machine interaction.
What's in Store for AmerisourceBergen (ABC) in Q1 Earnings?
by Zacks Equity Research
AmerisourceBergen's (ABC) Q1 earnings are likely to reflect the better-than-expected performance at Pharmaceutical Distribution and higher revenues.
Stryker (SYK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine are likely to have contributed to Stryker's (SYK) Q4 earnings.
PerkinElmer (PKI) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Top-line growth and robust performance at Diagnostics segment are likely to have aided PerkinElmer's (PKI) Q4 earnings. However, forex is likely to have remained a woe.
What's in the Cards for Intuitive Surgical (ISRG) Q4 Earnings?
by Zacks Equity Research
Better-than-expected performance at Instruments & Accessories segment and da Vince procedure growth are likely to have benefited Intuitive Surgical's (ISRG) Q4 earnings.
Minimally Invasive Surgery Gains Ground: 3 Stocks in Focus
by Trina Mukherjee
With minimally invasive surgery gaining momentum, these stocks are poised to capitalize on the market prospects.
5 ROE Stocks to Profit as Markets Bet on Imminent Trade Deal
by Supriyo Bose
ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.
The Zacks Analyst Blog Highlights: Medtronic, Apple, Stryker and Intuitive Surgical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Medtronic, Apple, Stryker and Intuitive Surgical
Industry 4.0 to Steer MedTech to Higher Growth: A Sneak Peek
by Urmimala Biswas
Investors need to be bold enough to bet on trend-shifting consumption habits emanating from Industry 4.0, which will stand them in good stead.
Stryker (SYK) Down 5.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Stryker (SYK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Intuitive Surgical (ISRG) Boosts da Vinci System With FDA Nod
by Zacks Equity Research
Intuitive Surgical (ISRG) is likely to strengthen its da Vinci surgical system with the recent FDA nod.
Here's Why You Should Hold on to Varian (VAR) Stock for Now
by Zacks Equity Research
Varian (VAR) gains from Oncology unit, deals with weakness in the Proton Therapy segment.
Zacks.com featured highlights include: CDW, Sony, Applied Materials, Stryker and Lam Research
by Zacks Equity Research
Zacks.com featured highlights include: CDW, Sony, Applied Materials, Stryker and Lam Research
5 ROE Stocks to Buy as Market Basks in Trade Deal Optimism
by Supriyo Bose
ROE is often used to compare the profitability of a company with other firms in the industry ??? the higher, the better.
5 Stocks With Solid Sales Growth to Keep an Eye on Right Now
by Swayta Shah
Sustained sales growth is one of the most important characteristics of potential winners in the stock market. It provides investors an insight into product demand and pricing power.
Top 5 ROE Stocks to Profit as Market Hits Record High Levels
by Supriyo Bose
ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.
Stryker (SYK) Q3 Earnings Meet Estimates, Revenues Beat
by Zacks Equity Research
Stryker's (SYK) Q3 earnings gain from higher revenues, solid segmental performance and strong organic growth across businesses benefit.
Stryker (SYK) Q3 Earnings Match Estimates
by Zacks Equity Research
Stryker (SYK) delivered earnings and revenue surprises of 0.00% and 0.17%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
ResMed's (RMD) Q1 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
ResMed (RMD) registers growth at CER across its key operating segments in Q1.
Integra LifeSciences' (IART) Earnings Top Estimates in Q3
by Zacks Equity Research
We are upbeat about the year-over-year revenue growth in Integra LifeSciences' (IART) Codman Specialty Surgical segment.
What's in the Offing for Stryker's (SYK) Earnings in Q3?
by Zacks Equity Research
Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine and an upbeat third quarter 2019 view are likely to have contributed to Stryker's (SYK) Q3 earnings.
Is Stryker (SYK) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (SYK) Outperforming Other Medical Stocks This Year?
Align Technology (ALGN) Beats on Q3 Earnings, Margins Fall
by Zacks Equity Research
We are upbeat about Align Technology (ALGN) witnessing continued momentum in Invisalign volumes across all geographies